All In Biotech

Drug Trial Radar · NCT00449956

MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

Multicenter, Double-Blind, Active Comparator-controlled Study to Evaluate the Safety and Efficacy of MK0507A in Patients With Glaucoma and Ocular Hypertension Who Are Inadequately Controlled on Beta-Blockers

Last checked: Nov 20, 2026Latest source record: Jun 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 474 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

474

Actual

Start

Mar 12, 2007

Primary completion

Feb 16, 2008

Study completion Feb 16, 2008

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular hypertension.

Conditions

  • Glaucoma

Interventions

  • dorzolamide hydrochloride (+) timolol maleateDrug

    Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week

  • Comparator: timolol maleateDrug

    timolol maleate 0.5%, 8-week

  • Comparator: dorzolamide hydrochlorideDrug

    dorzolamide hydrochloride 1%, 8-week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Intraocular Pressure (IOP) From Baseline at 8 WeeksTime frame: 8 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.